Board Change • Jul 09
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Chairman Niels Thestrup was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Annuncio • May 16
ChemoMetec A/S, Annual General Meeting, Oct 08, 2026 ChemoMetec A/S, Annual General Meeting, Oct 08, 2026. Annuncio • May 05
Chemometec A/S Upgrades Earnings Guidance for the Financial Year 2025/2026 ChemoMetec A/S upgraded earnings guidance for the financial year 2025/2026. For the year, the Company now expects revenue in the DKK 505 million - DKK 525 million range, up from DKK 490 million - DKK 520 million in the most recent guidance. To ensure continued compliance with the applicable accounting framework (IFRS), ChemoMetec has adjusted the allocation of revenue between instruments and services. Annuncio • Mar 26
ChemoMetec A/S Revises Earnings Guidance for the Year 2025/2026 ChemoMetec A/S revised earnings guidance for the year 2025/2026. For the year, the company expects revenue of DKK 490 million to DKK 520 million is now expected in the financial year 2025/26 against the most recently announced DKK 565 million to DKK 580 million. Annuncio • Feb 06
Chemometec A/S Maintains Earnings Guidance for the Year 2025 ChemoMetec A/S maintained earnings guidance for the year 2025. For the period, the company expects revenue in the range of DKK 565-580 million range. Annuncio • Oct 28
ChemoMetec A/S Updates Earnings Guidance for the Year 2025-26 ChemoMetec A/S updated earnings guidance for the year 2025-26. For the year, the company now expects revenue to be DKK 565 million - DKK 580 million against the most recently announced DKK 545 million- DKK 565 million. The company expects a positive trend in revenue and profit particularly in the last part of the financial year 2025/26. Annuncio • Oct 10
ChemoMetec A/S Approves to Distribute Dividend ChemoMetec A/S at the AGM held on 9 October 2025, approved to distribute a dividend of DKK 7 per share of a nominal value of DKK 1. Annuncio • Sep 18
ChemoMetec A/S, Annual General Meeting, Oct 09, 2025 ChemoMetec A/S, Annual General Meeting, Oct 09, 2025, at 17:30 Romance Standard Time. Location: nordsjaellands konferencecenter, gydevang 39-41, 3450 allerod, Denmark Annuncio • Jan 10
Chemometec A/S Updates Earnings Guidance for the 2024/2025 Financial Year ChemoMetec A/S updated earnings guidance for the 2024/2025 Financial year. For the year, company expected revenue in the DKK 470 million - DKK 490 million range, up from DKK 460 million - DKK 475 million in the most recent guidance. Annuncio • Dec 04
ChemoMetec A/S Updates Earnings Guidance for the Financial Year 2024-2025 ChemoMetec A/S updated earnings guidance for the financial year 2024-2025. For the year, the company now expected revenue to be in the range of DKK 460 million to DKK 475 million, up from DKK 445 million to DKK 460 million in the most recent guidance. Annuncio • Nov 08
ChemoMetec A/S Maintains Earnings Guidance for the Full-Year 2024-2025 ChemoMetec A/S maintained earnings guidance for the full-year 2024-2025. For the year, the company expects revenue to be in the range of DKK 445 million to DKK 460 million. Annuncio • Oct 23
ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA. ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA for €2.8 million on September 20, 2024. A cash consideration of €2.83 million will be paid by ChemoMetec A/S. As part of consideration, €2.83 million is paid towards common equity of Ovizio Imaging Systems NV/SA. For the period ending December 31, 2023, Ovizio Imaging Systems NV/SA reported total revenue of €1.4 million.
ChemoMetec now has three weeks to carry out a due diligence, and if the outcome of this is positive, ChemoMetec will most likely proceed with the acquisition. The transaction is subject to approval of offer by target shareholders, consummation of due diligence investigation and definitive agreement. The tender offer has already been accepted by shareholders owning more than two thirds of Ovizio, and ChemoMetec is currently in the process of obtaining acceptance from the remaining shareholders, who are under a legal obligation to accept. As of October 16, 2024, the deal has been approved by shareholders of Ovizio Imaging Systems NV/SA. Closing is expected to take place within the coming week and will coincide with the actual acquisition date.
ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA on October 22, 2024. Annuncio • Oct 17
ChemoMetec A/S Revises Earnings Guidance for the Financial Year 2024/2025 ChemoMetec A/S revised earnings guidance for the financial year 2024/2025. The company sustained its positive performance in the first quarter of 2024/2025 with better-than-expected sales and order intake. Based on this, the company now expects revenue for the 2024/2025 financial year in the DKK 445 million to DKK 460 million range, up from DKK 435 million to DKK 450 million in the most recent guidance. Annuncio • Oct 11
ChemoMetec A/S Approves Dividend ChemoMetec A/S at its Annual General Meeting held on 10 October 2024, approved the proposal of the Board of Directors to distribute a dividend of DKK 4 per share of a nominal value of DKK 1. Annuncio • Sep 21
ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA. ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA on September 20, 2024.
For the period ending December 31, 2023, Ovizio Imaging Systems NV/SA reported total revenue of €1.4 million.
The transaction is subject to consummation of due diligence investigation. Annuncio • Sep 12
ChemoMetec A/S provides earnings guidance for the year 2024/25 ChemoMetec A/S provided earnings guidance for the year 2024/25. For the period, the company expected revenue to be in the DKK 435 million to DKK 450 million range against DKK 407.4 million last year. Annuncio • May 25
ChemoMetec A/S Announces CFO Changes The board of ChemoMetec A/S appointed Kim Nicolajsen as new CFO with effect from 1 July 2024. Kim Nicolajsen comes from a similar position as CFO in the family-owned company Rohde Nielsen. He is state-authorized public accountant and has previously worked for KPMG and EY. The board has also entered into an agreement with the company's current CFO Niels Høy Nielsen that he will resign from his position at the same time as Kim Nicolajsen takes over. The board would like to thank Niels Høy Nielsen for his contribution to ChemoMetec and for the good cooperation. CEO Martin Helbo Behrens and CFO Kim Nicolajsen will hereafter form the executive management of ChemoMetec. Annuncio • Apr 13
ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24 ChemoMetec A/S provided earnings guidance for the year 2023/24. For the period, the company expected revenue to be in the DKK 400 million - DKK 415 million range against previously announced DKK 400 million - DKK 435 million and thus still within the most recently announced range. Annuncio • Mar 13
ChemoMetec A/S Announces CEO Changes The Board of Directors of ChemoMetec has decided to appoint the company's current COO Martin Helbo Behrens as new CEO, effective as of March 13, 2024. The decision is based on the Board’s assessment that ChemoMetec in the current phase of the company's development needs a different composition of executive management skills. Therefore, the board has entered into an agreement with the company's current CEO Rasmus Kofoed to resign from his position as of March 13, 2024. Martin Helbo Behrens, who is 31 years old, has been employed at ChemoMetec for a number of years. He was originally employed as part of Group Finance, but in 2021 he relocated to the USA to take up a position as first COO and then CFO of ChemoMetec's American subsidiary. In these roles he has made a significant contribution to ChemoMetec's high growth and commercial success in the North American market over recent years. After almost three years in the USA, Martin Helbo Behrens returned to ChemoMetec's head office in Allerød as Deputy COO in 2023 and took up the position as COO on 1 February 2024. With Martin Helbo Behrens' in-depth insight into ChemoMetec's organization, products and markets, and based on the results he has contributed to creating in ChemoMetec, the Board is convinced that Martin Helbo Behrens will be the right profile to head ChemoMetec as CEO in the future. CEO Martin Helbo Behrens and CFO Niels Høy Nielsen will hereafter form the executive management of ChemoMetec. Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to kr.528, the stock trades at a forward P/E ratio of 58x. Average trailing P/E is 49x in the Life Sciences industry in Europe. Total loss to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.238 per share. Annuncio • Feb 06
ChemoMetec A/S Maintains Earnings Guidance for the Year 2024 ChemoMetec A/S maintained earnings guidance for the year 2024. The company maintain full-year guidance for 2023/24 of revenue in the range of DKK 400 million - DKK 435 million and EBITDA in the range of DKK 200 million - DKK 220 million. Annuncio • Dec 21
ChemoMetec A/S Announces Executive Changes ChemoMetec A/S announced that COO and deputy chairman of the board Martin Glensbjerg has decided to step down in ChemoMetec to pass the baton on to the next generation. From 1 February 2024 until the end of 2024, he will act as Senior Advisor with reference to CEO Rasmus Kofoed. Martin Glensbjerg continues as deputy chairman of the board. In his new role, Martin Glensbjerg will, among other things, participate in the update of ChemoMetec's strategy and also contribute to ensuring a successful anchoring and launch of the upcoming new products, including XcytoMatic 40 and XcytoMatic 30. At the same time, Martin Helbo Behrens, Deputy COO, is appointed COO, and Bo Melholt Nielsen, Physicist & Project Manager, Chief R&D Officer. Both Martin Helbo Behrens and Bo Melholt Nielsen have been employed at ChemoMetec for a number of years. Before joining as Deputy COO earlier this year, Martin Helbo Behrens was CFO and COO in ChemoMetec's American subsidiary and was part of Group Finance before that. Bo Melholt Nielsen has a strong academic and professional background in physics, especially quantum optics, and as project manager for the development of XcytoMatic 40 and XcytoMatic 30 he has been a significant driving force behind the development of the new generation of products. Martin Glensbjerg was one of three co-founders when ChemoMetec was established in 1997, and since then he has held a leading position in the company and has made a significant contribution to ensuring that ChemoMetec has achieved an attractive global market position. Valuation Update With 7 Day Price Move • Sep 20
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to kr.334, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 29x in the Life Sciences industry in Europe. Total loss to shareholders of 23% over the past three years. Reported Earnings • Sep 16
Full year 2023 earnings released: EPS: kr.10.27 (vs kr.9.16 in FY 2022) Full year 2023 results: EPS: kr.10.27 (up from kr.9.16 in FY 2022). Revenue: kr.444.4m (up 3.7% from FY 2022). Net income: kr.178.7m (up 12% from FY 2022). Profit margin: 40% (up from 37% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. New Risk • Aug 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. High level of non-cash earnings (30% accrual ratio). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Annuncio • May 10
ChemoMetec A/S Affirms Earnings Guidance for the Fiscal Year 2022/2023 ChemoMetec A/S affirmed earnings guidance for the fiscal year 2022/2023. For the year, based on developments in the third quarter of 2022/23, guidance for financial year 2022/23, as announced in connection with the release of the interim report for 2022/23 on 8 February 2023, is maintained. Accordingly, revenue for 2022/23 is expected in the range of DKK 430 million - DKK 460 million. Reported Earnings • Feb 12
First half 2023 earnings released: EPS: kr.6.06 (vs kr.4.90 in 1H 2022) First half 2023 results: EPS: kr.6.06 (up from kr.4.90 in 1H 2022). Revenue: kr.242.7m (up 16% from 1H 2022). Net income: kr.105.4m (up 24% from 1H 2022). Profit margin: 43% (up from 41% in 1H 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Annuncio • Feb 09
ChemoMetec A/S Updates Earnings Guidance for the Fiscal Year 2022/2023 ChemoMetec A/S updated earnings guidance for the fiscal year 2022/2023. For the year, the company expected revenue of DKK 430 million - DKK 460 million, against the previous guidance of DKK 485 million-DKK 505 million. Valuation Update With 7 Day Price Move • Dec 21
Investor sentiment deteriorated over the past week After last week's 19% share price decline to kr.707, the stock trades at a trailing P/E ratio of 76.9x. Average trailing P/E is 42x in the Life Sciences industry in Europe. Total returns to shareholders of 262% over the past three years. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Oct 26
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Sep 23
Investor sentiment deteriorated over the past week After last week's 16% share price decline to kr.671, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 31x in the Life Sciences industry in Europe. Total returns to shareholders of 401% over the past three years. Reported Earnings • Sep 20
Full year 2022 earnings released: EPS: kr.9.16 (vs kr.5.08 in FY 2021) Full year 2022 results: EPS: kr.9.16 (up from kr.5.08 in FY 2021). Revenue: kr.428.4m (up 52% from FY 2021). Net income: kr.159.5m (up 81% from FY 2021). Profit margin: 37% (up from 31% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has increased by 69% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Sep 20
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Aug 25
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Aug 02
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Jul 14
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Jun 08
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 28
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Feb 10
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: EPS: kr.4.90 (up from kr.2.43 in 1H 2021). Revenue: kr.209.8m (up 58% from 1H 2021). Net income: kr.85.2m (up 101% from 1H 2021). Profit margin: 41% (up from 32% in 1H 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Nov 23
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Upcoming Dividend • Oct 08
Upcoming dividend of kr.4.00 per share Eligible shareholders must have bought the stock before 15 October 2021. Payment date: 19 October 2021. Trailing yield: 0.2%. Lower than top quartile of British dividend payers (4.1%). Lower than average of industry peers (0.4%). Reported Earnings • Sep 18
Full year 2021 earnings released: EPS kr.5.08 (vs kr.3.51 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: kr.281.1m (up 31% from FY 2020). Net income: kr.88.4m (up 49% from FY 2020). Profit margin: 31% (up from 28% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 133% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Sep 08
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Is New 90 Day High Low • Feb 20
New 90-day high: kr.620 The company is up 44% from its price of kr.431 on 20 November 2020. The British market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 31% over the same period. Reported Earnings • Feb 07
First half 2021 earnings released: EPS kr.2.43 (vs kr.1.68 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: kr.133.0m (up 28% from 1H 2020). Net income: kr.42.3m (up 54% from 1H 2020). Profit margin: 32% (up from 27% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has increased by 148% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Dec 08
New 90-day high: kr.459 The company is up 23% from its price of kr.374 on 09 September 2020. The British market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 12% over the same period. 
